Adeno-associated virus type 2 binds to a 150-kilodalton cell membrane glycoprotein

Virology
H MizukamiK E Brown

Abstract

Early events, including the identification of the cellular receptor, have not yet been described for adeno-associated virus (AAV) infection. In this study, the binding characteristics of AAV-2 to human cells were examined in two different assays. In a liquid-phase assay, in which binding of biotinylated virus to cells in suspension was measured, AAV-2 showed specific binding to four different permissive cell lines: HeLa S3, 293, D6, and KB cells. In contrast, AAV-2 binding to erythrocytes or to the nonpermissive cell line UT-7/Epo was negligible. AAV-2 binding showed saturation kinetics. Both binding and infectivity of AAV-2 were abolished by trypsin treatment of cells, with significant recovery of bindings after 8 hr of culture, suggesting that virus attachment occurs through a protein that can be regenerated on the cell surface. In a second, virus overlay assay, we assessed binding of [35S]methionine-labeled AAV-2 to membrane proteins that had been transferred to nitrocellulose after electrophoretic separation. In this assay, virus attachment was shown to a 150-kDa protein. This protein was present in membranes from the AAV-2 permissive cell lines but not detected in membranes from erythrocytes or UT-7/Epo cells. Enzymatic de...Continue Reading

Citations

Apr 23, 2002·Haemophilia : the Official Journal of the World Federation of Hemophilia·C E Walsh, H Chao
Feb 10, 1997·Human Gene Therapy·K M JohnstonX O Breakefield
Feb 23, 2000·Journal of Virology·J S BartlettR J Samulski
Sep 27, 2003·Journal of Virology·A KernJ A Kleinschmidt
Dec 15, 2004·Journal of Virology·Yuji KashiwakuraHiroyuki Daida
Nov 19, 2011·Journal of Dental Research·J C HsuK M Yamada
Nov 26, 2005·Uirusu·Syun-ichirou OshimaTakeshi Hirayama
Nov 5, 2002·Methods : a Companion to Methods in Enzymology·Jean-Charles Paterna, Hansruedi Büeler
Aug 11, 1997·Advanced Drug Delivery Reviews·M J During
Oct 19, 2004·Journal of Virological Methods·Qing XieMichael S Chapman
Sep 7, 2016·Current Opinion in Virology·Arun Srivastava
Jun 16, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·M GrifmanM D Weitzman
Apr 12, 2002·Molecular Therapy : the Journal of the American Society of Gene Therapy·Mihail Y MastakovMatthew J During
Jun 1, 2005·Molecular Therapy : the Journal of the American Society of Gene Therapy·Giovanni Di PasqualeBechara Kachar
Jan 19, 2018·Journal of Virology·Amanda M DudekLuk H Vandenberghe
Dec 13, 2005·Gene Therapy·H KatanoJ A Chiorini
Sep 23, 2003·Nature Medicine·Giovanni Di PasqualeJohn A Chiorini
Aug 25, 2017·Human Gene Therapy·Dirk Grimm, Hildegard Büning
May 6, 1999·Nature Medicine·J QiuK E Brown
Jun 18, 2003·The Journal of General Virology·Masayuki ImajohSyun-ichirou Oshima
Apr 10, 2019·Gene Therapy·Bradley A HamiltonJoseph Zabner
Oct 20, 2020·Trends in Molecular Medicine·Bijay P DhungelJohn E J Rasko
Jan 29, 2020·Molecular Therapy : the Journal of the American Society of Gene Therapy·Hildegard Büning
Nov 13, 1999·Journal of Virology·D DuanJ F Engelhardt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.